As illustrated in Figure 1A, EPHX2 expression was significantly downregulated in numerous cancer types, including bladder urothelial carcinoma (BLCA), BRCA, cholangiocarcinoma (CHOL), head and neck squamous cell carcinoma (HNSC), colon adenocarcinoma (COAD), kidney renal papillary cell carcinoma (KIRP), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), LIHC, LUAD, lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and UCEC. Here, EPHX2 is linked to chromophobe renal cell carcinoma.